Potential advantages of daprodustat compared to rhEPO and its analogs in the treatment of CKD anemia include that daprodustat raises Hb levels without exposing patients to supraphysiologic EPO levels, and that daprodustat can improve iron availability for erythropoiesis, which may reduce the need for iron supplementation and avoid the need for parenteral injection (Lenihan and Winkelmayer, 2016). The gene discussed is EPO; the disease is chronic kidney disease.